- Lobbying
- Lobbying by Sensiva Health, LLC
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Jason Van Pelt | Legislative Director, Senior Legislative Asst, Legislative Asst, Staff Asst: Rep. Ed Whitfield |
Hunter Moorhead | Policy Advisor, Sen. Thad Cochran; Special Asst to the President, WH National Economic Council; Professional Staff, Senate Approps Committee; Legislative Asst, Sen. Cochran; Subcommittee Staff Director/ Legislative Asst, House Agriculture Committee |
Shay Hancock | Military Legislative Assistant, Sen. Patty Murray; Legislative Assistant, Rep. Adam Smith |
Katherine Dapper | Staff Assistant, Sen. Patty Murray |
Salim Alameddin | Legislative Asst/Legislative Aide, Rep. Will Hurd; Legislative Correspondent/Staff Asst, Sen. John Cornyn |
Alex Gleason | Legislative Assistant, Legislative Aide, Legislative Correspondent, Rep. Ed Royce; Intern, Rep. Aaron Schock |
Jason Gleason | Chief of Staff/Legislative Director, Rep. John Sarbanes; Legislative Director/Legislative Asst/Legislative Correspondent/Staff Asst, Sen. Paul Sarbanes |
Stewart Hall | n/a |
John Green | n/a |
Mathew Lapinski | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Registration
Issue(s) they said they’d lobby about: Issues related to COVID-19 testing technology..
Termination
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Registration
Issue(s) they said they’d lobby about: COVID-19 testing.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate